The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Glofitamab, a CD20/CD3 bispecific antibody, in the treatment of R/R DLBCL
Lorenzo Falchi, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the role of glofitamab, a bispecific CD20-directed CD3 T-cell engager, in the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Following promising results from a pivotal trial (NCT03075696), glofitamab received FDA approval for third-line use in adults. Dr Falchi notes ongoing research is now investigating glofitamab in earlier lines of therapy, which is the focus of the ongoing Phase III SKYGLO trial (NCT06047080). This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory board: AstraZeneca, Genentech, Abbvie, Ipsen, ADC Therapeutics, Seagen; Consultancy: Genmab, Roche, Genentech, Abbvie, Evolveimmune; Honoraria: Genmab, Genentech, Abbvie; Travel Expenses: Genmab, Abbvie; Research Funding: Genmab, Roche, Genentech, Abbvie, Innate Pharma.
